Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
or

Evoke Pharma (EVOK)

Evoke Pharma (EVOK)
2.12 x 12 2.15 x 6
Post-market by (Cboe BZX)
2.15 unch (unch) 04/17/25 [NASDAQ]
2.12 x 12 2.15 x 6
Post-market 2.15 unch (unch) 15:59 ET
Quote Overview for Thu, Apr 17th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
2.02
Day High
2.15
Open 2.15
Previous Close 2.15 2.15
Volume 7,900 7,900
Avg Vol 20,820 20,820
Stochastic %K 21.53% 21.53%
Weighted Alpha -67.91 -67.91
5-Day Change -0.10 (-4.44%) -0.10 (-4.44%)
52-Week Range 1.94 - 12.32 1.94 - 12.32
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,210
  • Shares Outstanding, K 1,493
  • Annual Sales, $ 10,250 K
  • Annual Income, $ -5,350 K
  • EBIT $ -5 M
  • EBITDA $ -5 M
  • 60-Month Beta 0.30
  • Price/Sales 0.31
  • Price/Cash Flow N/A
  • Price/Book 0.45

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.94 +10.82%
on 04/15/25
Period Open: 3.49
3.57 -39.69%
on 03/18/25
-1.34 (-38.37%)
since 03/17/25
3-Month
1.94 +10.82%
on 04/15/25
Period Open: 4.40
5.40 -60.19%
on 02/13/25
-2.25 (-51.14%)
since 01/17/25
52-Week
1.94 +10.82%
on 04/15/25
Period Open: 6.59
12.32 -82.55%
on 10/28/24
-4.44 (-67.36%)
since 04/17/24

Most Recent Stories

More News
Evoke Pharma, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

EVOK : 2.15 (unch)
Evoke Pharma to Report Fourth Quarter and Full Year 2024 Results on March 13, 2025

EVOK : 2.15 (unch)
Evoke Pharma Announces the Appointment of Greg Pyszczymuka to the Board of Directors

EVOK : 2.15 (unch)
Evoke Pharma Addresses FDA Update on Domperidone Supply and Highlights GIMOTI as the Only Approved Treatment for Gastroparesis

Evoke Pharma highlights GIMOTI's role amid FDA's domperidone supply concerns, emphasizing its benefits for gastroparesis patients.Quiver AI SummaryEvoke Pharma, Inc. announces its commitment to addressing...

EVOK : 2.15 (unch)
Evoke Pharma Highlights GIMOTI as a Leading Solution for Gastroparesis Treatment as Domperidone Supply Ends

EVOK : 2.15 (unch)
Evoke Pharma Receives Patent Allowances Expanding Intellectual Property for GIMOTI® Nasal Spray Treatment for Gastroparesis

Evoke Pharma received patent allowances for GIMOTI nasal spray, enhancing its protection for treating diabetic gastroparesis.Quiver AI SummaryEvoke Pharma, Inc., a specialty pharmaceutical company focusing...

EVOK : 2.15 (unch)
Evoke Pharma Receives Notices of Allowance for Two Additional US Patent Applications Protecting GIMOTI®

EVOK : 2.15 (unch)
Evoke Pharma, Inc. Reports Third Quarter 2024 Financial Results

EVOK : 2.15 (unch)
Evoke Pharma & EVERSANA Announce Statistically Significant Improvement in Patient Outcomes for GLP-1 users with Diabetic Gastroparesis using GIMOTI®

EVOK : 2.15 (unch)
Evoke Pharma to Showcase Award-Winning Research at the 2024 American College of Gastroenterology Annual Scientific Meeting

EVOK : 2.15 (unch)
Evoke Pharma Announces the Appointment of Ben Smeal to the Board of Directors

EVOK : 2.15 (unch)
Evoke Pharma Reports Second Quarter 2022 Financial Results

Total new inbound prescriptions over 500 for first time, 24% increase over Q1; New cumulative prescribers up 23%; Net revenue increased by 11%...

EVOK : 2.15 (unch)
Evoke Pharma to Report Second Quarter Results on August 10, 2022

SOLANA BEACH, Calif., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for...

EVOK : 2.15 (unch)
Evoke Pharma Recognizes Gastroparesis Awareness Month through its Support of The International Foundation for Gastrointestinal Disorders (IFFGD)

Ranked #1 in IFFGD Virtual Walk to spread awareness and support research for gastrointestinal disorders Evoke attending ANMS 2022 meeting August 5-7...

EVOK : 2.15 (unch)
Evoke Pharma Announces Approval of GIMOTI® to Florida State Medicaid Program

SOLANA BEACH, Calif., June 15, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on...

EVOK : 2.15 (unch)
Evoke Pharma Regains Compliance with Nasdaq Listing Requirements and Provides Financial Update

SOLANA BEACH, Calif., June 08, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on...

EVOK : 2.15 (unch)
Real-World Data Analysis Reveals a Lower Risk of Tardive Dyskinesia (TD) with Metoclopramide than Previously Reported

Presented as a Poster of Distinction at Digestive Disease Week (DDW) 2022, showed a 98.8 per 100,000 (0.1%) incidence of TD among gastroparesis patients...

EVOK : 2.15 (unch)
Evoke Pharma to Report First Quarter 2022 Financial Results on May 10, 2022

SOLANA BEACH, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for...

EVOK : 2.15 (unch)
Evoke Pharma Reports Fourth Quarter and Full Year 2021 Financial Results

Fourth-quarter net product sales from prescriptions increased by 46% to $361,000 versus Q3 Easing of COVID-19 restrictions helped fuel higher sales,...

EVOK : 2.15 (unch)
Evoke Pharma to Report Fourth Quarter and Full Year 2021 Financial Results on March 8, 2022

SOLANA BEACH, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for...

EVOK : 2.15 (unch)

Business Summary

Evoke Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. The Company's lead product candidate, EVK-001, is in late stage clinical testing which is intended for the treatment of diabetic gastroparesis. Evoke...

See More

Key Turning Points

3rd Resistance Point 2.33
2nd Resistance Point 2.24
1st Resistance Point 2.20
Last Price 2.15
1st Support Level 2.06
2nd Support Level 1.97
3rd Support Level 1.93

See More

52-Week High 12.32
Fibonacci 61.8% 8.35
Fibonacci 50% 7.13
Fibonacci 38.2% 5.91
Last Price 2.15
52-Week Low 1.94

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Unlock High-Probability Trade Setups: Master Fractals & Time Frames Like a Pro

Info When You Need It Most.

Barchart Premier is one of the most powerful tools in the investment world. Come see why so many subscribers love it — and try it risk-free for 30 days.